AMG-319

AMG-319 is a highly selective, potent, and orally bioavailable small molecule inhibitor of the delta isoform of class IA phosphoinositide 3‑kinases (PI3Kδ). It was developed by Amgen as an immunomodulatory and antineoplastic agent. The drug inhibits PI3Kδ activity by blocking the production of phosphatidylinositol‑3,4,5‑trisphosphate (PIP3), thereby reducing cell proliferation and inducing cell death. PI3Kδ is primarily expressed in hematopoietic cells; its inhibition preferentially affects regulatory T cells (Tregs), leading to their displacement from tumors and increased cytotoxicity of CD8+ T cells. This mechanism underlies its potential use in cancer immunotherapy as well as autoimmune diseases such as rheumatoid arthritis. Clinical trials have evaluated AMG‑319 in relapsed or refractory lymphoid malignancies and solid tumors including head and neck squamous-cell carcinoma[1][2][4][5][8].

Other names

(S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine1608125-21-8